Tirzepatide has been evaluated in clinical trials involving adults with type 2 diabetes and individuals with obesity or overweight. Its safety profile includes gastrointestinal reactions that are particularly common during treatment initiation and dosage increases. Many reported symptoms are mild to moderate, although some patients experience reactions that require medical attention.
Common side effects associated with tirzepatide include:
Nausea: A frequently reported reaction, particularly when beginning treatment or increasing the dosage.
Diarrhea: Changes in digestive activity can cause loose or frequent bowel movements.
Vomiting: Some individuals experience vomiting, which may contribute to dehydration.
Constipation: Delayed stomach emptying and changes in digestion can affect bowel movements.
Abdominal discomfort: Stomach pain, indigestion, and bloating may occur during treatment.
Reduced appetite: Tirzepatide influences appetite regulation and can decrease food consumption.
Clinical safety information also identifies potential serious complications, including acute pancreatitis, gallbladder disease, severe gastrointestinal reactions, kidney injury associated with dehydration, and allergic reactions. Hypoglycemia may occur, particularly when tirzepatide is combined with insulin or insulin secretagogues.
Animal studies identified thyroid C-cell tumors. However, whether this risk applies to humans remains unknown. Tirzepatide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It is also not recommended for people with severe gastroparesis.
Long-term clinical research helps researchers understand how tirzepatide performs beyond the initial treatment period. Studies such as SURPASS and SURMOUNT have examined blood glucose regulation, weight reduction, treatment tolerability, and adverse events over extended periods.
The SURMOUNT-4 clinical trial investigated continued tirzepatide treatment for maintaining weight reduction. Participants initially received tirzepatide for 36 weeks before entering a 52-week randomized treatment period. The findings demonstrated the importance of continued treatment in maintaining weight reduction among participants who had already responded to therapy.
Other research has examined several important areas:
Long-term blood glucose control: Researchers evaluate changes in HbA1c levels and overall glycemic management during continued treatment.
Weight management: Studies assess whether weight reduction can be maintained with ongoing medication use.
Cardiovascular safety: Clinical investigations examine cardiovascular outcomes, including heart attacks, strokes, and cardiovascular deaths.
Kidney health: Researchers evaluate kidney-related outcomes and potential complications associated with dehydration.
Treatment tolerability: Extended studies monitor gastrointestinal symptoms, discontinuation rates, and other adverse reactions.
Dosage considerations: Research examines how different prescribed doses influence treatment outcomes and tolerability.
The SURPASS-CVOT trial also examined cardiovascular outcomes in adults with type 2 diabetes and increased cardiovascular risk. Its findings provide additional information about the cardiovascular safety profile of tirzepatide compared with dulaglutide.
Ongoing monitoring remains important throughout treatment. Healthcare professionals may assess blood glucose levels, kidney function when clinically indicated, digestive symptoms, hydration, and changes in existing health conditions. Patients should also inform healthcare professionals about other medications, pregnancy plans, and upcoming surgical procedures because tirzepatide can affect gastric emptying and oral medication absorption.
Long-term safety research continues to examine outcomes that may require observation beyond the duration of individual clinical trials. Current evidence provides information about its established risks and treatment outcomes, while some potential effects of many years of continuous use remain under investigation.